TABLE 2.

Linezolid concentrations in plasma, ELF, and ACa

BAL sampling time (h)Concn in plasma 12 h after the fourth dose (μg/ml)bConcn (μg/ml) at the indicated BAL sampling time in:
PlasmaACELFc
47.3 ± 4.9 (2.3-14.2)15.5 ± 4.9 (8.9-22)2.2 ± 0.6 (1.7-3.1)64.3 ± 33.1 (43.2-123)d
87.0 ± 2.6 (4.2-10.6)8.9 ± 3.2 (5.1-13)1.5 ± 2.0 (0.5-5.0)31.4 ± 33.0 (8.3-89.2)
127.6 ± 1.7 (6.0-9.6)e10.2 ± 2.3 (6.8-12.6)1.4 ± 1.3 (0.5-3.6)24.3 ± 13.3 (10.2-45.9)
247.6 ± 1.1 (6.2-9.1)1.8 ± 0.6 (0.9-2.4)0.2 ± 0.1 (0-0.3)7.6 ± 6.0 (1.5-17)
486.0 ± 3.3 (2.8-10.4)0.2 ± 0.2 (0.02-0.5)BLQf0.7 ± 0.8 (0-2)
  • a Data are means ± 1 SD; ranges are given in parentheses.

  • b There were no significant differences among the plasma linezolid concentrations at 12 h after the fourth dose (P > 0.05).

  • c ELF drug concentrations at 4, 8, 12, and 24 h were significantly greater than AC drug concentrations at the same times (P < 0.05).

  • d Concentrations in ELF at 4 h were significantly greater than those at 8, 12, 24, and 48 h (P < 0.05).

  • e n = 4.

  • f BLQ, below level of quantitation.